| Literature DB >> 32964812 |
Xin Wu1, Binglu Li1, Chaoji Zheng1, Wei Liu1, Tao Hong1, Xiaodong He1.
Abstract
PURPOSE: Medullary thyroid carcinoma is a rare endocrine malignancy; 75% of patients with this disease have sporadic medullary thyroid carcinoma. While surgery is the only curative treatment, the benefit of prophylactic lateral neck dissection is unclear. This study aimed to analyze the clinicopathological risk factors associated with lateral lymph node metastases and determine the indication for prophylactic lateral neck dissection in patients with sporadic medullary thyroid carcinoma.Entities:
Keywords: central lymph node; lateral lymph node; metastases; risk factor; sporadic medullary thyroid carcinoma
Year: 2020 PMID: 32964812 PMCID: PMC7517989 DOI: 10.1177/1533033820962089
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
Figure 1.Flow diagram of the selection process of patients included in this study. Forty-two patients had undergone primary surgery at other hospitals before they were transferred to our facility for radical repeat-surgery. Twenty-two of them who lacked detailed pathological information of their primary surgeries were excluded; the remaining 20 could provide their pathological reports and were therefore included.
Clinicopathological Characteristics of the 125 Patients With SMTC.
| Characteristic | Value |
|---|---|
| Sex, male/female (n) | 46/79 |
| Age (years) | 48.8 ± 11.2 |
| BMI (kg/m2) | 23.9 ± 3.3 |
| Major tumor size (cm) | 2.0 ± 1.3 |
| Total tumor size (cm) | 2.2 ± 1.8 |
| Central lymph node metastases (n) | 59 (47.2%) |
| Lateral lymph node metastases (n) | 49 (39.2%) |
| Neutrophil-to-lymphocyte ratio | 2.4 ± 1.4 |
| Platelet-to-lymphocyte ratio | 155.3 ± 87.8 |
SMTC: sporadic medullary thyroid carcinoma; BMI: body mass index.
The continuous variables are presented as the means ± standard deviations.
Figure 2.Characteristic sonographic features of medullary thyroid carcinoma and metastatic lymph nodes. A, Longitudinal ultrasound section of the right thyroid lobe, showing a well-defined hypoechogenic tumor with irregular contours and internal microcalcifications. B, Transverse ultrasound section of the same lesion. C, Central compartment of the same patient, showing ovoid, probably metastatic lymph nodes without hilum. D, Lateral compartment of the same patient, showing ovoid hypoechogenic lesion without echogenic hilum.
Demographic Data and Test Results of Patients With SMTC.
| Factors | Total (n = 125) | Lateral lymph node metastases | p | |
|---|---|---|---|---|
| (+) (n = 49) | (−) (n = 76) | |||
| Male n(%) | 46 (36.8%) | 23 (46.9%) | 23 (30.1%) | 0.059 |
| Age (years) | 48.8 ± 11.2 | 50.3 ± 9.6 | 47.9 ± 12.2 | 0.210 |
| BMI (kg/m2) | 23.9 ± 3.3 | 23.8 ± 3.4 | 23.9 ± 3.3 | 0.787 |
| Smoking n(%) | 15 (12.0%) | 8 (16.3%) | 7 (9.2%) | 0.232 |
| HT n(%) | 17 (13.6%) | 2 (4.1%) | 15 (19.7%) | 0.013 |
| FT3 (pg/mL) | 3.1 ± 0.4 | 3.0 ± 0.3 | 3.1 ± 0.4 | 0.119 |
| FT4 (ng/dL) | 1.2 ± 0.2 | 1.2 ± 0.2 | 1.2 ± 0.2 | 0.443 |
| TSH (μIU/mL) | 2.3 ± 1.6 | 2.6 ± 1.7 | 2.1 ± 1.5 | 0.100 |
| CT >30 pg/mL n(%) | 36 (28.8%) | 19 (38.8%) | 17 (22.4%) | 0.048 |
| CEA >15 ng/mL n(%) | 27 (21.6%) | 15 (30.6%) | 12 (15.8%) | 0.049 |
| NLR | 2.4 ± 1.4 | 2.2 ± 1.0 | 2.4 ± 1.5 | 0.364 |
| PLR | 155.3 ± 87.8 | 143.9 ± 55.7 | 162.7 ± 103.0 | 0.244 |
| lateral lymph nodes (+) on ultrasonography n(%) | 36 (28.8%) | 34 (69.4%) | 2 (2.6%) | <0.001 |
SMTC: sporadic medullary thyroid carcinoma; BMI: body mass index; HT: Hashimoto’s thyroiditis; FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyroid-stimulating hormone; CT: calcitonin; CEA: carcinoembryonic antigen; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.
The continuous variables are presented as the means ± standard deviations.
Pathology Results of Patients With SMTC.
| Factors | Total (n = 125) | Lateral lymph node metastases | p | |
|---|---|---|---|---|
| (+) (n = 49) | (−) (n = 76) | |||
| Left/right lobe (n) | 65/60 | 25/24 | 40/36 | 0.860 |
| Multifocality n(%) | 20 (16.0%) | 9 (18.4%) | 11 (14.5%) | 0.562 |
| Bilaterality n(%) | 17 (13.6%) | 7 (14.3%) | 10 (13.2%) | 0.857 |
| Major tumor size (cm) | 2.0 ± 1.3 | 2.2 ± 1.6 | 1.8 ± 1.1 | 0.065 |
| Total tumor size (cm) | 2.2 ± 1.8 | 2.5 ± 2.3 | 1.9 ± 1.3 | 0.087 |
| Capsular invasion n(%) | 34 (27.2%) | 22 (44.9%) | 12 (15.8%) | <0.001 |
| Extrathyroidal invasion n(%) | 11 (8.8%) | 8 (16.3%) | 3 (3.9%) | 0.039 |
| Ki67 ≥5% n(%) | 20 (16.0%) | 9 (18.4%) | 11 (14.5%) | 0.562 |
| Positive central LNM n(%) | 59 (47.2%) | 39 (79.6%) | 20 (26.3%) | <0.001 |
SMTC: sporadic medullary thyroid carcinoma; LNM: lymph node metastases.
The continuous variables are presented as the means ± standard deviations.
Multivariate Analysis of Risk Factors for Lateral LNM Among Patients With SMTC.
| p | OR | 95% CI | |
|---|---|---|---|
| lateral lymph nodes (+) on ultrasonography | <0.001 | 101.747 | 14.666–705.869 |
| positive central LNM | 0.001 | 9.764 | 2.610–36.523 |
| CT >30 pg/mL | 0.120 | ||
| CEA >15 ng/mL | 0.252 | ||
| Hashimoto’s thyroiditis | 0.240 | ||
| Capsular invasion | 0.640 | ||
| Extrathyroidal invasion | 0.873 |
LNM: lymph node metastases; SMTC: sporadic medullary thyroid carcinoma; OR: odds ratio; CI: confidence interval; CT: calcitonin; CEA: carcinoembryonic antigen.
Clinicopathologic Features of Patients With Negative Lateral Lymph Nodes on Preoperative Ultrasonography.
| Factors | Total (n = 89) | Lateral lymph node metastases | P | |
|---|---|---|---|---|
| (+) (n = 15) | (−) (n = 74) | |||
| Male n(%) | 28 (31.5%) | 7 (46.7%) | 21 (28.4%) | 0.277 |
| Age (years) | 48.5 ± 11.5 | 50.4 ± 7.9 | 48.1 ± 12.1 | 0.371 |
| CT >30 pg/mL n(%) | 18 (20.2%) | 1 (6.7%) | 17 (23.0%) | 0.280 |
| CEA >15 ng/mL n(%) | 15 (16.9%) | 3 (20.0%) | 12 (16.2%) | 1.000 |
| Multifocality n(%) | 14 (15.7%) | 3 (20.0%) | 11 (14.9%) | 0.913 |
| Bilaterality n(%) | 12 (13.5%) | 3 (20.0%) | 9 (12.2%) | 0.692 |
| Total tumor size (cm) | 1.9 ± 1.3 | 1.5 ± 0.9 | 1.9 ± 1.3 | 0.244 |
| Capsular invasion n(%) | 15 (16.9%) | 3 (20.0%) | 12 (16.2%) | 1.000 |
| Extrathyroidal invasion n(%) | 4 (4.5%) | 1 (6.7%) | 3 (4.1%) | 0.529 |
| positive central LNM n(%) | 30 (33.7%) | 10 (66.7%) | 20 (27.0%) | 0.003 |
CT: calcitonin; CEA: carcinoembryonic antigen.
The continuous variables are presented as the means ± standard deviations.